These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7778056)

  • 21. Effects of a thromboxane A2-receptor antagonist, a thromboxane synthetase inhibitor and aspirin on prostaglandin I2 production in endothelium-intact and -injured aorta of guinea pigs.
    Higo K; Karasawa A
    Jpn J Pharmacol; 1994 Dec; 66(4):471-9. PubMed ID: 7723224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
    Imura Y; Terashita Z; Shibouta Y; Nishikawa K
    Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
    Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
    J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of various antiplatelet agents on acute arterial thrombosis in the rat.
    Bernat A; Mares AM; Defreyn G; Maffrand JP; Herbert JM
    Thromb Haemost; 1993 Nov; 70(5):812-6. PubMed ID: 8128439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
    [No Abstract]   [Full Text] [Related]  

  • 26. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective and nonselective inhibition of thromboxane formation.
    FitzGerald GA; Oates JA
    Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
    Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
    Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia.
    Bhatia P; Kaur G; Singh N
    Vascul Pharmacol; 2021 Apr; 137():106827. PubMed ID: 33346090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin.
    Nagatsuka K; Uyama O; Nakabayashi S; Yoneda S; Kimura K; Kamada T
    Stroke; 1985; 16(5):806-9. PubMed ID: 3931302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model.
    Suehiro A; Oura Y; Ueda M; Kakishita E
    Res Commun Chem Pathol Pharmacol; 1994 Feb; 83(2):157-63. PubMed ID: 8202629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
    Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
    Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat.
    De Clerck F; Van Gorp L; Beetens J; Verheyen A; Janssen PA
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):247-58. PubMed ID: 2151728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
    Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
    Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
    Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
    J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of CV-4151, a selective inhibitor of thromboxane synthetase, on prostanoid formation and platelet aggregation in humans.
    Kuzuya T; Kimura Y; Hoshida S; Kodama K; Nakamura N; Hamanaka Y; Kitabatake A; Kamada T; Tada M
    Cardiovasc Drugs Ther; 1988 Dec; 2(5):693-700. PubMed ID: 3154645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.